Pentair shares are trading lower after the company cut its FY26 EPS guidance below estimates. Also, the company cut its Q2 guidance below estimates.

Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 for a Leadership Role

Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against Capricor Therapeutics, Pentair plc, and Bloom Energy Corporation on behalf of investors who suffered losses. The primary case involves Capricor, where the FDA released briefing documents revealing that the company made undisclosed changes to its statistical analysis plan for a drug application, resulting in a 64% stock price drop on July 27, 2026.

TD Cowen Maintains Sell on Pentair, Lowers Price Target to $65

Baird Maintains Outperform on Pentair, Lowers Price Target to $80

Why Pentair Is Spending $1.4 Billion To Ride The AI Data Center Wave

Pentair (PNR) stock rises despite Q2 earnings miss after announcing a $1.4B acquisition of Taco Group Holdings.